Beyond Cancer (Beyond Air) gets Israeli MoH approval for Phase 1b LV UNO + anti-PD-1 trial for solid tumors

Beyond Air, Inc.

Israeli Ministry of Health approved Phase 1b trial of LV UNO in combination with anti-PD-1 therapy for solid tumors.
Trial will enroll up to 20 patients with unresectable solid tumors that progressed or were stable on PD-1 inhibitors.
Primary endpoint: objective response rate (ORR) and duration of response per RECIST v1.1; secondary immune-related response.
Four Israeli sites; patient screening Q1 2025; topline data expected second half of 2025.
Preclinical data showed single UNO dose increased PD-L1 expression and improved survival vs anti-PD-1 alone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.